Fresh Equities
PARADIGM BIOPHARMACEUTICALS LIMITED

PARADIGM BIOPHARMACEUTICALS LIMITED

ASX:PAR

Last Placement
Bidding Closed
Offer Price
$1.5000
Discount to Close
21.05%
Raised
$51.6M
Last Close
$1.9000
Market Cap at Close
$266.56M
Relisted
Apr 17, 2019

Company Information

Paradigm Biopharmaceuticals Limited (PAR) is an Australian biopharmaceutical company focused on repurposing the drug 'pentosan polysulphate sodium' (PPS) for the treatment of bone marrow edema. Paradigm is targeting addressable markets with the aim to use the shortened development pathway utilising repurposed drugs.

Type

Listed Company

GICS Sub-Industry

Biotechnology

Head Office

Level 2/517 Flinders Ln, Melbourne VIC 3000, Australia

Biotechnology
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.